Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcus Biosciences (RCUS) Operating Expenses (2017 - 2025)

Arcus Biosciences has reported Operating Expenses over the past 9 years, most recently at $147.0 million for Q4 2025.

  • Quarterly results put Operating Expenses at $147.0 million for Q4 2025, up 13.95% from a year ago — trailing twelve months through Dec 2025 was $633.0 million (up 7.65% YoY), and the annual figure for FY2025 was $633.0 million, up 7.65%.
  • Operating Expenses for Q4 2025 was $147.0 million at Arcus Biosciences, down from $168.0 million in the prior quarter.
  • Over the last five years, Operating Expenses for RCUS hit a ceiling of $168.0 million in Q2 2025 and a floor of $73.6 million in Q4 2021.
  • Median Operating Expenses over the past 5 years was $112.0 million (2023), compared with a mean of $120.0 million.
  • Biggest five-year swings in Operating Expenses: soared 172.66% in 2021 and later decreased 6.83% in 2025.
  • Arcus Biosciences' Operating Expenses stood at $73.6 million in 2021, then soared by 46.74% to $108.0 million in 2022, then rose by 12.96% to $122.0 million in 2023, then increased by 5.74% to $129.0 million in 2024, then rose by 13.95% to $147.0 million in 2025.
  • The last three reported values for Operating Expenses were $147.0 million (Q4 2025), $168.0 million (Q3 2025), and $168.0 million (Q2 2025) per Business Quant data.